Houdini Bio

Houdini Bio, a University of Cambridge spinout focused on advancing gene and cell therapies, has secured nearly £1.5 million in pre-seed funding to further develop its machine learning-powered platform.

Summary of transaction details:

• Value: £1,500,000
• Sector: Healthcare & Biotech
• Advisor: Not mentioned
• Key Entities: Target: Houdini Bio; Lead Investor: SCVC (Science Creates); Other Investors: Deep Science Ventures, Cambridge Enterprise VC
• Location: Cambridge

Note: This funding round will enable Houdini Bio to accelerate the development of its novel technology, which aims to improve the efficacy and safety of gene and cell therapies by enhancing the longevity and potency of therapeutic DNA within the body, addressing critical challenges in the future of medicine.